Research detection kit Bupreen®

for tumour detectionfor BRAF mutationsfor EGFR mutations

The International Agency for Research on Cancer ( IARC ) has released the latest statistics on the global cancer burden ( based on data for 2022 ), and once again highlighted the current increasing global cancer burden, which deserves worldwide attention. According to the report, in 2022, there are an estimated 20 million new cancer cases worldwide, and about 9.7 million people died of cancer. It is estimated that the number of survivors within 5 years after cancer diagnosis is about 53.5 million. About 1 / 5 of people will have cancer in their lives, about 1 / 9 of men and 1 / 12 of women died of cancer .It is estimated that by 2050, there will be more than 35 million new cancers worldwide. Cancer is a complex, multi-gene disease caused by the gradual accumulation of genetic mutations. When genes that regulate cell growth undergo mutations or damage, cells lose control and undergo uncontrolled and unlimited proliferation and differentiation, leading to the development of malignant tumors. With the advent of precision medicine in cancer treatment, conventional pathological diagnostic methods are no longer sufficient to meet clinical demands. International guidelines and consensuses recognize the value of comprehensive molecular testing based on Next-Generation Sequencing (NGS) in guiding clinical treatment. Comprehensive and accurate tumor genetic diagnostic results have become an essential requirement in clinical diagnosis and treatment. DETECTION SIGNIFICANCE 1. Targeted Therapy：Provide comprehensive tumor gene mutation information, including tumor-related pathway gene information and rare sites,